Home Blog Page 1018

Bitcoin Rally to Two-Month High Signals Shift in Crypto Derivatives Sentiment, Bybit and Block Scholes Find

DUBAI, UAE, Jan. 15, 2026 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, has released the latest Bybit x Block Scholes Crypto Derivatives Analytics report showing that Bitcoin’s rise to a two-month high is prompting early signs of a shift in derivatives market sentiment.

Key findings:

  • Bitcoin’s breakout to a two-month high has coincided with rising perpetual futures open interest and higher funding rates for several altcoins.
  • Short-dated Bitcoin and Ether options have moved toward a neutral volatility skew after a prolonged bearish bias.
  • Futures term structures for Bitcoin and Ether have clustered at similar levels, indicating consistent pricing of risk across maturities.

The analysis finds that Bitcoin’s recent move into the upper $90,000 range, following more than a month of rangebound trading, has had a notable impact across futures and options markets. Open interest in perpetual futures has increased across major digital assets, signaling new long positions as traders position for potential continuation of the rally. Funding rates for select altcoins have also moved higher, reflecting improved risk appetite.

Options markets are showing a parallel adjustment. Volatility smiles for short-dated Bitcoin and Ether options have shifted toward a neutral skew after previously pricing in a bearish put premium. Despite the sharp spot price move, implied volatility has remained relatively subdued, suggesting markets are recalibrating expectations rather than anticipating immediate turbulence.

“Cryptos have braved past geopolitical shockers at the onset of 2026, appearing intent on catching up with other risk assets,” said Han Tan, Chief market analyst at Bybit Learn. “Recent gains bode well for our 2026 Bitcoin target of $150,000, though the road ahead will likely be marked by turbulence as geopolitical and U.S. monetary policy risks cloud the macro outlook.”

Spot market dynamics continue to support prices. Year-to-date inflows into Bitcoin and Ether spot exchange-traded funds remain positive, reinforcing demand during the latest breakout. Ether has also benefited from on-chain factors, with roughly 30 percent of its circulating supply now staked, tightening available supply.

The report highlights the $94,000 to $96,000 price region as a key trigger for sentiment changes in derivatives markets. A similar move earlier this month briefly pushed options skews to neutral before reversing when prices failed to hold. The latest breakout has again shifted positioning, though analysts note that a sustained move above these levels may be required for a more decisively bullish options skew to emerge.

The full Bybit x Block Scholes report provides detailed analysis of spot, futures, and options markets and is available for download.

#Bybit / #CryptoArk / #BybitLearn

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

 

SOLAR & STORAGE LIVE THAILAND 2026: LEADING THE FUTURE OF SUSTAINABLE ENERGY IN THAILAND

BANGKOK, Jan. 15, 2026 /PRNewswire/ — Thailand is set to make significant strides towards a sustainable future as Solar & Storage Live Thailand 2026 returns to Bangkok on 28 – 29 January 2026 at the Bangkok International Trade & Exhibition Centre (BITEC).

As Thailand accelerates its transition towards clean energy, the free expo and conference organised by Terrapinn will bring together over 5,000 industry leaders, developers, installers, policymakers, solution providers, investors, and innovators under one roof. With 80+ leading sponsors and exhibitors, and 200+ expert speakers, the event will serve as a critical platform for driving the expansion of solar and storage technologies in Thailand.

Amidst the global call for urgent action against climate change, Thailand is at the forefront of renewable energy adoption, leveraging its abundant natural resources to power a sustainable tomorrow. Solar & Storage Live Thailand 2026 underscores the nation’s commitment to embracing clean energy solutions and fostering innovation in the energy sector.

The event has garnered strong support from key government agencies and industry partners, including the Ministry of Energy, Ministry of Industry, Electricity Generating Authority of Thailand (EGAT), Metropolitan Electricity Authority (MEA), Provincial Electricity Authority (PEA) and more, reinforcing its position as Thailand’s leading solar and storage marketplace.

Solar & Storage Live Thailand 2026’s free-to-attend exhibition will offer attendees the chance to evaluate solutions from leading energy players such as Ningbo Deye Inverter Technology, RAPD Solar Cell, Mars Rock Thailand, Enercore, TMDA Electric, GoodWe, and many more.

“We’re delighted to be returning to Bangkok once again with the only established event focusing on the tremendous opportunity that solar & energy storage represent for securing Thailand’s energy future. Thousands of leaders have already signed up to shop for solutions, learn about the latest trends and build relationships with potential partners”, says Paul Clark, Managing Director at Terrapinn Pte Ltd.

In addition to the exhibition, the event will feature five free-to-attend conference tracks exploring the policies, business models and technologies defining Thailand’s energy future. Confirmed speakers include senior leaders from government, utilities and industry, such as:

  • Ploylapas Singtothong, Ministerial Adviser to the Minister of Industry, Minister of Industry (MIND)
  • Suwita Shotuk, Chief, Hydro and Renewable Energy, Power Plant Electrical Engineering Department, Electricity Generating Authority of Thailand (EGAT)
  • Sittiporn Somkitsan, Director General Department of Traffic and Transport, Bangkok Metropolitan Administration (BMA)
  • Athita Vivatpinyo, Manager, Advanced Energy Systems, Asia Clean Energy Partners
  • Mrutyunjaya Nanda, Team Leader, Technology and Markets, Asia Clean Energy Partners
  • Lertnapa Pittapundu, Director, Napa Enterprise Co., Ltd.
  • Vichshuwan Pungchareon, Senior Manager, Center of Digital Energy, BCPG Public Company Limited
  • Dr. Dhirayut Chenvidhya, Director, CES Solar Cells Testing Center (CSSC), King Mongkut’s University of Technology Thonburi (KMUTT)
  • Syed Muhammad Khubaib, International Business Representative, YC Solar
  • Dr. Phimsupha Kokchang, Researcher, Energy Research Institute
  • Yanika Chanapo, Senior Investment Officer, Norfund
  • Perapol Umpaivit, General Manager, Getz Energy
  • Pitirat Wongwattanakij, Co-founder, P&N Intergroup Supply Co., Ltd.
  • Prof. Dr. Supot Teachavorasinskun, President Board of Advisory Committee, Center of Excellence in Electrical Power Technology (CEPT)
  • Wirittipol Somdulyawat, Chief of Public Sector Customer Care Section 3, Better Care and Power Quality Department, Metropolitan Electricity Authority
  • Piyapong Prachuab, Electrical Engineer, Smart Grid and Electrical Systems Planning Division, Metropolitan Electricity Authority
  • Watcharapong Khemkaew, President, Wind Energy Association of Thailand (WEAT)
  • Supharerk Yimgobkit, President, Thai Biogas Trade Association
  • Chaphamon Chantrapongphan, President, Thai Photovoltaic Industries Association (TPVA)
  • Thawee Chongkavinit, Vice Chairman, The Renewable Energy Industry Club (RE-FTI Club)

Solar & Storage Live Thailand is co-located with EVCharge Live Thailand, Highways Thailand, and Mobility Live Thailand, creating a comprehensive and multi-sector platform for industry professionals to explore renewable energy, electric vehicle charging, smart mobility, and transportation infrastructure. This unique convergence enables cross-industry collaboration, integrated solution discovery and deeper insights into the future of sustainable mobility and energy development in Thailand. Bringing together these four pivotal events will foster innovation and drive advancements that will shape the future of Thailand’s infrastructure and energy landscape.

Press attendance is complimentary. Enquiries should be directed to:
Judith Soh, Marketing Manager
Terrapinn Pte Ltd
Judith.soh@terrapinn.com

For more information, please visit www.terrapinn.com/SolarPress-PRN 

PRNewswire is the Official Media Partner of Solar & Storage Live Thailand 2026.

About Terrapinn

Terrapinn has been sparking ideas, innovations and relationships that transform business for over 30 years. Using our global footprint, we bring innovators, disrupters and change agents together, discussing and demonstrating the technology, strategies and personalities that are changing the way the world does business. Whether you’re looking to make new connections, introduce product or inspire change in your industry, we invite you to join us as agitators of change. Terrapinn – spark something https://www.terrapinn.com/

Amcor Completes One-for-Five Reverse Stock Split

ZURICH, Jan. 15, 2026 /PRNewswire/ — Amcor plc (NYSE: AMCR; ASX: AMC), a global leader in developing and producing responsible packaging solutions, announced today it has completed its previously announced 1-for-5 reverse stock split.

The reverse stock split was approved by Amcor shareholders at its annual general meeting of shareholders held on November 6, 2025.  Amcor filed an amendment to its memorandum of association to effect the reverse stock split on January 14, 2026.

Amcor ordinary shares began trading on a split-adjusted basis on the New York Stock Exchange (“NYSE”) today and shares continue to trade under the symbol “AMCR” with a new CUSIP number, which is G0250X 149.  Amcor’s CHESS Depositary Interests (“CDIs”) continue to trade under the symbol “AMC” and are also now trading on a split-adjusted basis.

Amcor’s transfer agent, Computershare, is acting as exchange agent for the reverse stock split. Registered U.S. shareholders who hold their shares directly may contact Computershare toll free at 1-866-526-3029 (within the U.S.), or at 1-617-668-3920.  Holders of CDIs may contact Computershare toll free at 1300 850 505 (within Australia) or at +61 3 9415 4000 (outside of Australia).  If you hold your shares with a broker, queries should be directed to your broker.

Additional information concerning the reverse stock split can be found in Amcor’s definitive proxy statement filed with the Securities and Exchange Commission on September 23, 2025, as well as on Amcor’s Investor Relations website, https://www.amcor.com/investors.

About Amcor

Amcor is the global leader in developing and producing responsible consumer packaging and dispensing solutions across a variety of materials for nutrition, health, beauty and wellness categories. Our global product innovation and sustainability expertise enables us to solve packaging challenges around the world every day, producing a range of flexible packaging, rigid packaging, cartons, and closures, that are more sustainable, functional and appealing for our customers and their consumers. We are guided by our purpose of elevating customers, shaping lives and protecting the future. Supported by a commitment to safety, over 75,000 people generate $23 billion in annualized sales from operations that span over 400 locations in more than 40 countries. NYSE: AMCR; ASX: AMC

www.amcor.com  I  LinkedIn  I  YouTube

Aptean Receives Frost & Sullivan’s 2026 Global Technology Innovation Leadership Recognition for Excellence in AI-powered ERP for Food and Beverage

Aptean is proud to have been recognized as a global Technology Innovation Leader for redefining AI-powered ERP solutions that enhance efficiency, productivity, and operational intelligence in the food and beverage industry.

SAN ANTONIO, Jan. 15, 2026 /PRNewswire/ — Frost & Sullivan is pleased to announce that Aptean, a global leader in AI-powered enterprise software for industrial sectors, has been recognized with the 2026 Global Technology Innovation Leadership Recognition in the AI-powered ERP for Food and Beverage industry, for its outstanding achievements in advancing AI-driven innovation, customer value, and operational excellence. This recognition highlights Aptean’s role as a Technology Innovation Leader, driving measurable outcomes, strengthening its market position, and delivering customer-centric intelligence in an increasingly competitive landscape.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. Aptean excelled in both, demonstrating its ability to align strategic initiatives with market demand while executing them with precision, scale, and speed.

“Aptean is an AI driven company and the recent launch of AppCentral is a pivotal moment in Aptean’s evolution to Vertical AI platform leader. Its AI strategy is powered by industry-specific insights, and it streamlines and enables faster, smarter business operations for customers. Aptean champions AI as a transformative force that is essential for delivering tailored intelligence and innovative solutions, thereby driving efficiency, fostering innovation, and ensuring industry success,” said Sankara Narayanan, Industry Director at Frost & Sullivan.

Frost & Sullivan’s evaluation finds that Aptean’s AppCentral ecosystem represents a significant advancement in the evolution of AI-powered ERP for the food and beverage industry. The platform’s unified architecture, combined with Aptean’s deep vertical expertise, enables organizations to streamline complex processes, enhance visibility, and accelerate data-driven decision making across the value chain. AppCentral’s role-based AI workspaces, predictive analytics, and intelligent automation capabilities deliver meaningful operational benefits, supporting customers as they navigate rising market pressures and increasing digital demands. Frost & Sullivan recognizes that Aptean’s ability to translate its AI strategy into practical, scalable innovation has been central to its success and reinforces its position as a global leader in technology innovation.

“We’re proud to be recognized by Frost & Sullivan’s research leading the next generation of food and beverage ERP innovation,” said TVN Reddy, CEO of Aptean. “This is a pivotal point as we take our strategy to the next level, empowering our customers in a data-driven, AI-first world. And with the advent of AppCentral, we’re delivering not just robust AI capabilities, but also purpose-built agents and value-added solutions to streamline everyday work and provide actionable intelligence.”

Aptean Food and Beverage on AppCentral embodies our commitment to deploying AI that is deeply rooted in industry needs and directly connected to how food and beverage organizations operate. With more than 250 product enhancements delivered in the past 3 years, and solid ongoing investment in R&D, the evolution of the AI enabled Aptean Food and Beverage ERP solutions ensure that customers gain not just smarter tools, but a continuously evolving ecosystem designed to help them stay ahead of demand, complexity, and change,” said Ioana Vintila, Director of Product Marketing for Food and Beverage ERP, Aptean

Guided by a long-term growth strategy focused on digital innovation, industry specialization, and customer partnership, Aptean has shown its ability to adapt and lead in a rapidly evolving marketplace. The company’s strategic agility and sustained investment in AI-driven ERP innovation have enabled it to scale effectively across diverse regions and industries.

Innovation remains central to Aptean’s approach. Its AI‑powered ERP solutions help food and beverage companies tackle challenges across processing, production, inventory, and distribution. With deep industry expertise and advanced technologies, Aptean enables manufacturers and distributors to boost efficiency, profitability, and data‑driven decision‑making.

Frost & Sullivan commends Aptean for setting a high standard in competitive strategy, innovation, and customer responsiveness. The company’s AI vision, robust innovation pipeline, and customer-first culture are shaping the future of the global ERP landscape and driving measurable transformation in the food and beverage sector.

Each year, Frost & Sullivan presents the Technology Innovation Leadership Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. This distinction honors forward-thinking organizations that are reshaping their industries through innovation and growth excellence.

Frost & Sullivan Best Practices Recognition

Frost & Sullivan’s Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.
Contact us: Start the discussion.

About Aptean

Aptean is a global provider of industry-specific software that helps manufacturers and distributors effectively run and grow their businesses. Aptean’s solutions and services help businesses of all sizes to be Ready for What’s Next, Now®. Aptean is headquartered in Alpharetta, Georgia and has offices in North America, Europe and Asia-Pacific.

To learn more about Aptean and the markets we serve, visit www.aptean.com.

Aptean and Ready for What’s Next, Now are Registered Trademarks of Aptean, Inc. All other company and product names may be trademarks of the respective companies with which they are associated.

Contact:

Ioana Vintila
Director, Product Marketing
Aptean, Inc.

TOTALENERGIES PARTNERS WITH BLUENERGIES IN ITS HARPER BASIN FAN PLAY, OFFSHORE LIBERIA

TSXV: BLU

VANCOUVER, BC, Jan. 15, 2026 /PRNewswire/ — BluEnergies Ltd. (TSXV: BLU) (“BLU” or the “Company“) is pleased to report it has successfully entered into an industry standard joint study and application agreement (“JSAA“) with the Liberian upstream subsidiary of TotalEnergies SE (NYSE: TTE) (“TTE“), in order to further explore the prospectivity of the Company’s deep water fan play in the Harper Basin, offshore Liberia. The West Africa Transform Margin, where the Harper Basin is located, and its conjugate South American Margin are regions where the basin floor fan play is being actively, successfully explored, developed and produced.

JSAA Highlights

The purpose of the JSAA between BLU and TTE is to further unlock the prospective potential of the Harper Basin blocks by establishing prospects within LB-26, LB-30 and LB-31 (the “Blocks“). Subject to establishing economically viable drillable prospects, BLU and TTE intend to apply for one or several production sharing contracts covering the desirable Blocks. An immediate budget has been jointly committed for the execution of a work program during the next 18 months involving state-of-the-art seismic reprocessing for more accurate reservoir imaging and the acquisition of sea bottom data, in order to fully evaluate the prospectivity and de-risk the hydrocarbon potential. This work program comprises:

(a) 

the reprocessing by TGS ASA (Oslo) (“TGS“), a leading provider of advanced data and intelligence in the energy sector, of 6,167 km² (~1.5 million acres) of original 3-D seismic data initially acquired by TGS in 2013, covering the majority of the Blocks. This program commenced November 28, 2025; and

(b) 

offshore sea bottom new data acquisition comprising multi-beam/backscatter, heat flow survey and subsequent data studies and interpretation.

New Liberia Reconnaissance License

To support the JSAA between TTE and the Company, the Liberian subsidiaries of BLU and TTE have entered into a new Reconnaissance License LPRA-003 (“RL-003“) with the Liberia Petroleum Regulatory Authority (“LPRA“) covering these contiguous Blocks with an areal extent of 8,924 km² (~ 2.2 million acres). Key provisions of RL-003 are:

  1. BLU has a 35% participating interest and TTE has a 65% participating interest in RL-003. 
  2. BLU and TTE are required to conduct a work program that includes state-of-the-art 3-D reprocessing and sea bottom new data acquisition.
  3. The term of RL-003 continues up to June 30, 2027, with new RL-003 replacing BLU’s existing Reconnaissance License LPRA-002 (“RL-002“).
  4. Reconnaissance expenditures under RL-003 and RL-002 would be recoverable under any future production sharing contracts covering the Blocks. Under the RL-002 work program, which required a minimum expenditure of US$1,600,000, BLU spent US$1,862,000 (CA$2,570,000).

Background 

During October 2024, under RL-002 held 100% by BLU, the Company acquired from TGS a review license of the 6,167 km2 3-D seismic survey covering a majority of the Blocks. As a result of the Company’s interpretation of the 3-D survey, BLU delineated seven large scale discrete Cretaceous aged basin floor fans.

In Q1 2025, the Company entered into negotiations under non-disclosure agreements with numerous deepwater operators. As a result of these broad-based negotiations, BLU accepted an exclusive relationship with TTE in July 2025 and thereafter entered into a non-binding memorandum of understanding on October 8, 2025. Final negotiations led the Company to successfully enter into the JSAA with TTE under the new RL– 003.

About BluEnergies Ltd.

BluEnergies Ltd. is a Canadian-based international oil and gas exploration and development company with a focus on operations in West Africa. For additional information on BluEnergies Ltd., please refer to the Company’s website, www.blu-energies.com.

Forward-looking Information

This news release contains “forward-looking statements” and “forward-looking information” (collectively, “forward-looking information“) within the meaning of applicable securities laws. Forward-looking information can be identified by words such as: “intend”, “believe”, “estimate”, “expect”, “may”, “will” and similar references to future periods. Examples of forward-looking information include, among others, the future plans of BLU, and information herein relating to BLU and its business plans, including the potential exploration and other planned activities in joint venture with TTE under possible production sharing contracts. Although BLU believes that, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because BLU can give no assurance that they will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by this information depending on, among other things, the risk that the future plans of BLU may differ from those that currently are contemplated. Additional risks include those disclosed in the management information circular of Canadian Global Energy Corp., which is available on the Company’s profile at SEDAR+ at www.sedarplus.ca. Readers are cautioned not to place undue reliance on forward-looking information. The Company undertakes no obligation to update any of the forward-looking information in this news release, except as otherwise required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

For further information, please contact: Craig Steinke, Chief Executive Officer, Investor Relations Inquiries, Email: info@blu-energies.com

AMTD, Owner of L’Officiel and AMTD IDEA Brands, Launches Litigation against Jalou Family for Malicious Falsehood, Defamation, and Consequential Loss and Damage

PARIS, LONDON and NEW YORK, Jan. 15, 2026 /PRNewswire/ — AMTD Group Inc. (“AMTD Group”), AMTD IDEA Group (NYSE: AMTD; SGX: HKB), AMTD Digital Inc. (NYSE: HKD) and The Generation Essentials Group (“TGE”, NYSE: TGE; LSE: TGE), a subsidiary of AMTD Digital Inc., jointly announce that AMTD IDEA Group has commenced legal action against Mr Benjamin Eymere of the Jalou Family, in connection with serious defamatory action against the Group, as well as misconduct including bad faith harassment of the Group’s staff and executives.

Mr Eymere was a former employee of a subsidiary of the Group, and he was summarily dismissed due to his misconduct and mismanagement. He attempted to file an appeal in the Paris Court, but his actions have been continuously dismissed.

Moreover, Mr Eymere’s recent actions involving misconduct and bad faith have required AMTD to take legal actions, importantly to correct baseless allegations and misstatements in relation to the Group’s L’Officiel and AMTD IDEA brands, which have been recently mentioned in certain press and social media publications. 

AMTD has already made formal reports to law enforcement authorities in connection with Mr Eymere’s present and past misconduct. 

AMTD firmly believes that the rule of law and fairness and justice will prevail, and looks forward to correcting and dispelling any slander or defamatory statements which might have been made against it.

On an overall basis, we take the opportunity to highlight certain evident inaccuracies in certain press and social media induced by Mr Eymere and/or the Jalou family:

1) The Duly Completed Acquisition of 100% of L’Officiel in 2022 : The L’Officiel Brand was acquired in 2022 primarily from Gem Global Yield LLC SCS (GGY), which is part of Global Emerging Markets (GEM), a $3.4 billion alternative investment group, focusing on emerging markets with diverse investment vehicles like management buyouts, PIPE’s (Private Investments in Public Equities), and venture investments (see official announcements by GEM as lead seller https://www.gemny.com/wp-content/uploads/2022/05/GEM-AMTD-PRESS-RELEASE-from-Paris-France-FINAL-Version.pdf and AMTD as the buyer https://ir.amtdinc.com/press-releases/news-details/2022/AMTD-International-Acquires-Global-Fashion-Media-Group-LOfficiel-Inc-SAS/default.aspx, in which both sides confirm that the AMTD acquisition has been completed with 100% of purchase price duly paid).

2) Since the AMTD’s acquisition as a “white knight” investor, L’Officiel has not incurred any debt or engaged in liabilities for business, and L’Officiel nowadays is financially strong with solid equity base

3) The controlling shareholder from which AMTD acquired the business was GEM, not the Jalou family, nor Mr Eymere. The Jalou family was not a controller nor a majority shareholder in L’Officiel at the time of acquisition.

AMTD would also strongly emphasize that it will tirelessly prosecute and continue legal action against any wrongdoers which seek to harm its reputation and breach the law. We are confident that our perseverance and commitment will inevitably bring justice and fairness, without reservations.

About AMTD Group

AMTD Group is a conglomerate with a core business portfolio spanning across media and entertainment, education and training, and premium assets and hospitality sectors.

About AMTD IDEA Group

AMTD IDEA Group (NYSE: AMTD; SGX: HKB) represents a diversified institution and digital solutions group connecting companies and investors with global markets. Its comprehensive one-stop business services plus digital solutions platform addresses different clients’ diverse and inter-connected business needs and digital requirements across all phases of their life cycles. AMTD IDEA Group is uniquely positioned as an active super connector between clients, business partners, investee companies, and investors, connecting the East and the West. For more information, please visit www.amtdinc.com or follow us on X (formerly known as “Twitter”) at @AMTDGroup.

About AMTD Digital Inc.

AMTD Digital Inc. (NYSE: HKD) is a comprehensive digital solutions platform headquartered in France. Its one-stop digital solutions platform operates key business lines including digital media, content and marketing services, investments as well as hospitality and VIP services. For AMTD Digital’s announcements, please visit https://ir.amtdigital.net/investor-news.

About The Generation Essentials Group

The Generation Essentials Group (NYSE: TGE; LSE: TGE), jointly established by AMTD Group, AMTD IDEA Group (NYSE: AMTD; SGX: HKB) and AMTD Digital Inc. (NYSE: HKD), is headquartered in France and focuses on global strategies and developments in multi-media, entertainment, and cultural affairs worldwide as well as hospitality and VIP services. TGE comprises L’Officiel, The Art Newspaper, movie and entertainment projects. Collectively, TGE is a diversified portfolio of media and entertainment businesses, and a global portfolio of premium properties. Also, TGE is a special purpose acquisition company (SPAC) sponsor manager, with its first SPAC successfully raised and priced on December 18, 2025.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor”provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,””anticipates,” “aims,” “future,” “intends,” “plans,” “believes,””estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about the beliefs, plans, and expectations of AMTD IDEA Group, AMTD Digital and/or The Generation Essentials Group, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in the filings of AMTD IDEA Group, AMTD Digital and The Generation Essentials Group with the SEC. All information provided in this press release is as of the date of this press release, and none of AMTD IDEA Group, AMTD Digital and The Generation Essentials Group undertakes any obligation to update any forward-looking statement, except as required under applicable law.

Gorilla Technology to Host Live Investor Webinar and Q&A on January 28

London, United Kingdom – Newsfile Corp. – January 15, 2026 – Gorilla Technology Group Inc. (NASDAQ: GRRR) (“Gorilla” or the “Company”), a global solution provider in AI-driven Security Intelligence, Network Intelligence, Business Intelligence and IoT technology, announced that it will participate in an investor webinar coordinated by RedChip to discuss the Company’s latest milestones on January 28, 2026, at 4:15 p.m. ET.

The webinar will feature Gorilla’s Chairman and CEO, Jay Chandan and CFO, Bruce Bower, who will provide an update on the Company’s strategy, technology buildout, strategic partnerships and key objectives for 2026.

With more than 24 years of operating history, 29 granted patents, and a rapidly expanding global footprint, Gorilla is executing against a growing pipeline exceeding $7 billion, supported by strong demand for GPU-as-a-Service infrastructure, AI-powered smart cities, and mission-critical security platforms. Recent milestones include a transformational $1.4 billion, multi-year partnership to deploy AI-ready data centers across Southeast Asia, continued expansion of national public safety programs in Asia and Latin America, and reaffirmed 2025 revenue guidance of $100-$110 million with EBITDA margins of 20-25%. For full year 2026, the Company currently expects revenue in the range of $137 million to $200 million, reflecting increasing scale, multi-year contract visibility, and sustained momentum across its global portfolio.

A question-and-answer session will follow the presentation. Investors are encouraged to send their questions in advance or during the webinar to GRRR@redchip.com

To register for the free webinar, please visit: https://www.redchip.com/webinar/GRRR/83305104264

About Gorilla Technology Group Inc.

Headquartered in London U.K., Gorilla is a global solution provider in Data Centres, Security Intelligence, Network Intelligence, Business Intelligence and IoT technology. We provide a wide range of solutions, including Smart City, Network, Video, Security Convergence and IoT, across select verticals of Government & Public Services, Manufacturing, Telecom, Retail, Transportation & Logistics, Healthcare and Education, by using AI and Deep Learning Technologies. Our expertise lies in revolutionizing urban operations, bolstering security and enhancing resilience. We deliver pioneering products that harness the power of AI in intelligent video surveillance, facial recognition, license plate recognition, edge computing, post-event analytics and advanced cybersecurity technologies. By integrating these AI-driven technologies, we empower Smart Cities to enhance efficiency, safety and cybersecurity measures, ultimately improving the quality of life for residents.

For more information, please visit our website: Gorilla-Technology.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Gorilla’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “might” and “continues,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, statements regarding our beliefs about future revenues and our ability to convert our pipeline, win additional projects and execute definitive contracts related thereto, along with those other risks described under the heading “Risk Factors” in the Form 20-F Gorilla filed with the SEC on April 30, 2025 and those that are included in any of Gorilla’s future filings with the SEC. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside of the control of Gorilla and are difficult to predict. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Gorilla undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.

Public Relations Contact:
Samantha Dowd
Prosek Partners
GRRR@prosek.com

Investor Relations Contact:
Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
GRRR@redchip.com

The issuer is solely responsible for the content of this announcement.

SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting

HIGHLIGHTS

  • Following an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review Committee (SRC) confirms the trial will continue with no modifications to the protocol.

Patient population

  • With the SECuRE trial continuing to recruit, a total of nine participants who had evaluable data by the 25th of November 2025 were included in the interim assessment by the SRC, with the majority of participants receiving at least two cycles of 8 GBq of 67Cu-SAR-bisPSMA each by the data cut-off date.
  • Seven participants received 67Cu-SAR-bisPSMA and two participants were treated with a combination of 67Cu-SAR-bisPSMA with enzalutamide.
  • Most participants were heavily pre-treated (with 55.6% having received more than 5 previous anti-cancer regimens) and had bone metastasis (66.7%).

Safety

  • The safety profile of 67Cu-SAR-bisPSMA remains favourable with most related adverse events (AEs) in the Cohort Expansion to date being Grade 1 or 2. The most common AEs were nausea and lymphopenia (observed in 33.3% of participants, for each AE).

Efficacy

  • Six participants had at least two prostate specific antigen (PSA) results following 67Cu-SAR-bisPSMA administration, with all showing a decrease in PSA. Of those, four participants (66.7%) thus far had a reduction of more than 50% in PSA (PSA50) and two participants (33.3%) had a reduction of more than 80% (PSA80).
  • One participant who presented with bone metastasis at enrolment achieved undetectable PSA with no prostate cancer detected by computed tomography (CT) or bone scan following 67Cu-SAR-bisPSMA treatment. The participant reported having excellent quality of life following the treatment.

Next Steps

  • The SECuRE trial will continue enrolment into the Cohort Expansion Phase with planned completion of recruitment in 2026. Phase III registrational trial planning ongoing based on data generated to date.

SYDNEY, Jan. 15, 2026 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to share a number of updates on the SECuRE trial following an SRC meeting. The SRC has recommended that the trial continue with the Cohort Expansion Phase (Phase II) as planned with no modifications to the protocol. The interim results assessed by the SRC were collected from nine participants enrolled in the cohort that had evaluable data by the cut-off date of the 25th of November 2025 and continue to show promising efficacy and a favourable safety profile of 67Cu-SAR-bisPSMA.

The majority of the nine participants had bone metastasis at enrolment (66.7%) and received multiple lines of previous treatments (more than 5 previous anti-cancer regimens, 55.6%). Median PSA prior to 67Cu-SAR-bisPSMA treatment was 18.9 ng/mL (range 1.5-30.2 ng/mL). Six out of these nine participants received at least 2 cycles of 8 GBq of 67Cu-SAR-bisPSMA each, with two of them also receiving concomitant enzalutamide.

Of the nine participants included in this SRC analysis, six had at least two PSA results following their 67Cu-SAR-bisPSMA treatment by the data cut-off date. Of these six participants, thus far four (66.7%) showed reductions in PSA of 50% or more (PSA50) and two (33.3%) showed reductions of 80% or more (PSA80).

The safety profile of 67Cu-SAR-bisPSMA remains favourable in the Cohort Expansion, with the majority of related AEs being Grade 1 or 2. The most common related AEs were nausea and lymphopenia (observed in three out of nine participants [33.3%], for each AE). The only AE that was Grade 3 or above was lymphopenia observed in three participants, some of whom had bone metastasis at baseline and/or had received multiple lines of therapy, including taxane and an investigational agent, prior to enrolment in the SECuRE study. There have been no overall renal toxicity or electrocardiogram (ECG) changes observed in these participants. In the combination enzalutamide arm, no new AEs (or worsening of AEs) related to 67Cu-SAR-bisPSMA have been observed to date.

Trial participant with no detectable disease after 3 cycles of 67Cu-SAR-bisPSMA

One of the participants in the Cohort Expansion was a 64-year-old man with bone metastases and baseline PSA of 5.4 ng/mL prior to entering the SECuRE study. Following his first cycle of 67Cu-SAR-bisPSMA, this participant showed a dramatic 95.2% reduction in PSA. He went on to receive 2 more cycles of 67Cu-SAR-bisPSMA and achieved undetectable PSA levels. In a follow-up bone scan and CT no metastatic disease was observed. This participant only exhibited mild (Grade 1) related AEs, most of which were gastrointestinal events, with no haematological or renal AEs observed. The participant reported having excellent quality of life following the treatment.

Lesion uptake of 64Cu-SAR-bisPSMA positron emission tomography (PET) at baseline (left image) and following two cycles of 67Cu-SAR-bisPSMA (8 GBq each; right image). PET image on the right was acquired 1 month after the 2nd cycle. Coloured arrows indicate representative metastatic bone lesions within each region: red – skull; blue – ribs and sternum; orange – spine; green – pelvis. Images shown as maximum intensity projections.
Lesion uptake of 64Cu-SAR-bisPSMA positron emission tomography (PET) at baseline (left image) and following two cycles of 67Cu-SAR-bisPSMA (8 GBq each; right image). PET image on the right was acquired 1 month after the 2nd cycle. Coloured arrows indicate representative metastatic bone lesions within each region: red – skull; blue – ribs and sternum; orange – spine; green – pelvis. Images shown as maximum intensity projections.

The interim data from this Phase II continues to confirm the favourable safety profile and promising efficacy seen in previous cohorts of the SECuRE trial[1] and supports the continuation of the trial with the aim to progress to a registrational Phase III study.

Clarity’s Executive Chairperson, Dr Alan Taylor, commented, “SAR-bisPSMA continues generating world-class data in both theranostic and diagnostic trials. The combination of the optimised dimer ‘bis’ structure with the benefits of copper isotopes, enabled by the proprietary sarcophagine technology, is proving to have created a product that is here to challenge the current treatment and diagnostic paradigms in radiopharmaceuticals.

“We have already seen a glimpse of the effects of 67Cu-SAR-bisPSMA through our Dose Escalation cohorts with additional and similar data being generated in the Cohort Expansion phase, demonstrating once again excellent efficacy and safety results of 67Cu-SAR-bisPSMA.

“All of the participants with evaluable data treated in the Phase II to date have shown declines in PSA, with the majority showing PSA decreases of more than 50% and mostly having only mild or moderate AEs. Most of these patients have been treated with more than 5 systemic treatment regiments and had bone metastasis prior to entering the SECuRE study. Although the number of participants with evaluable data to date is small, it is incredible to see yet another extraordinary case where a patient who had bone metastasis prior to entering the study achieved undetectable PSA following 67Cu-SAR-bisPSMA treatment, with no disease observed by anatomical and molecular imaging at the last assessments. This participant only experienced mild, transient AEs, most being gastrointestinal, and has reported having excellent quality of life following the treatment.

“Importantly, the work we have undertaken during the Dose Escalation Phase is now continuing to provide a strong foundation for us as we look ahead at protocol development and dosing for our Phase III clinical trial and commercialisation. As the participant numbers continue to increase with the trial enrollment, we continue to see very promising responses over and over again, giving us more confidence about the future of this product and its potential for commercialisation in metastatic castration-resistant prostate cancer (mCRPC). With three Fast Track Designations for the SAR-bisPSMA product and positive interactions with the US Food and Drug Administration (FDA) to date, we are working towards bringing this agent to clinicians and their patients around the world through the entirety of the prostate cancer journey, from first diagnosis to late-stage disease. All of these indications, being imaging in pre-definitive therapy and biochemical recurrence, as well as therapy in mCRPC, are blockbuster markets individually for prostate-specific membrane antigen (PSMA) targeted products, with an estimated combined market value of approximately US$10-15 billion by 2030. We are committed to continuing the development of this product, aiming to bring improved diagnostic and treatment options for prostate cancer in various stages of their disease.”

About the SECuRE trial

The SECuRE trial (NCT04868604)[2] is a Phase I/IIa theranostic trial for identification and treatment of participants with PSMA-expressing mCRPC using 64Cu/67Cu-SAR-bisPSMA. 64Cu-SAR-bisPSMA is used to visualise PSMA-expressing lesions and select candidates for subsequent 67Cu-SAR-bisPSMA therapy. The trial is a multi-centre, single arm, dose escalation study with a cohort expansion involving approximately 54 participants in the US. The overall aim of the trial is to determine the safety and efficacy of 67Cu-SAR-bisPSMA for the treatment of prostate cancer.

The SECuRE trial consists of the Dose Escalation (Phase I) and Cohort Expansion (Phase II) Phases. Based on the data from the Dose Escalation Phase, which demonstrated a favourable safety profile and efficacy of 67Cu-SAR-bisPSMA, the SECuRE trial progressed to the Cohort Expansion (Phase II) at an 8 GBq dose level as per the SRC recommendation (up to 6 cycles per patient in total)[3].

Cohort 2 of the Dose Escalation phase of the trial, where participants were dosed with 8 GBq of 67Cu-SAR-bisPSMA, demonstrated a very low rate of related AEs while all three participants achieved PSA declines of 80% or more (PSA80)[1]. The Dose Escalation Phase also showed high PSA response rates of the mCRPC in the pre-chemotherapy setting with a favourable safety profile: 92% of pre-chemotherapy participants (12/13) demonstrated PSA drops greater than 35%, PSA reductions greater than 50% were reached in 61.5% (8/13) of participants, and reductions of 80% or more were achieved in 46.2% (6/13) of participants[1]. These results supported the progress of the trial to its Cohort Expansion Phase using 8 GBq multi-dose in participants who had not received chemotherapy in the mCRPC setting.

Recruitment is currently ongoing into the Cohort Expansion Phase which will include 24 participants. A subset of participants will be treated with the combination of 8 GBq of 67Cu-SAR-bisPSMA with enzalutamide (androgen receptor pathway inhibitor [ARPI]), in line with the positive results from the Enza-p trial[4] and previous discussions with and advice from key global medical experts in the field of prostate cancer, including the Company’s Clinical Advisory Board members, Prof Louise Emmett and Prof Oliver Sartor, as well as the SRC.

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word “bis”, which reflects a novel approach of connecting two PSMA-targeting agents to Clarity’s proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy.

67Cu-SAR-bisPSMA and 64Cu-SAR-bisPSMA are unregistered products. The safety and efficacy of 67Cu-SAR-bisPSMA and 64Cu-SAR-bisPSMA have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that these products will become commercially available.

About Prostate Cancer

Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide[5]. Prostate cancer is the second-leading causes of cancer death in American men. The American Cancer Institute estimates in 2025 there will be about 313,780 new cases of prostate cancer in the US and around 35,770 deaths from the disease[6].

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing TCTs based on its SAR Technology Platform for the treatment of cancers.

www.claritypharmaceuticals.com

For more information, please contact:

Clarity Pharmaceuticals

Dr Alan Taylor                                      

Lisa Sadetskaya

Executive Chairperson                               

Director, Corporate Communications

ataylor@claritypharm.com                       

lisa@claritypharm.com

References

  1. Clarity Pharmaceuticals. SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences. https://www.claritypharmaceuticals.com/news/secure-update/
  2. ClinicalTrials.gov Identifier: NCT04868604, https://clinicaltrials.gov/ct2/show/NCT04868604
  3. Clarity Pharmaceuticals. SECuRE trial update: First patient treated in the Phase II Cohort Expansion. https://www.claritypharmaceuticals.com/news/secure-fp-phase2/
  4. Emmett L et al. ENZA-p Trial Investigators; Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2025 Mar;26(3):291-299. doi: 10.1016/S1470-2045(25)00009-9.
  5. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21834
  6. American Cancer Society: Key Statistics for Prostate Cancer. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html

This announcement has been authorised for release by the Executive Chairperson.